KLDO





Kaleidoscope Venture Capital, Inc – KLDO

3/26/2013 – Why KLDO appears to be ready to run with the boys

The time to buy KLDO is NOW.  As you know, last year I took a starter position in KLDO after finding it on one of my very successful scan techniques.  Mostly, it caught my eye because it was trading near its 52 week low, coming down from $0.13 to $0.0012, all on significantly low volume.  KLDO had and still has a fantastic share structure.  KLDO’s Authorized Share count is 400,000,000, and KLDO’s current Outstanding Share count is 137,894,523, with the Float being 114,175,523.  What I found when I started to look into the company, was a hidden GEM.  What I now believe I know, motivates me to share the below DD with you.  Here’s why KLDO is the largest position in my current portfolio.

Back in September, KLDO was on the verge of some very large deals and the long awaited release of the PALs network and Kiosks around the US. Ron Tate, CEO of the company, took the time to speak to us about their current plans, which I feel is imperative for you to listen to, so I posted it below.  What I want you to pay attention to, and feel free to write it down, is what they claimed was about to happen with where their business was going, which prompted the stock to go up over 400% in anticipation of the company updating us on some progress.  Well they later incurred a programming glitch, which I will discuss below, that caused a delay in the business, and a low volume drop to where the stock currently is today.  However, they are closer NOW then ever.  Please watch the below video, and read the below DD on why KLDO may become they next 10,000% gainer from this stock.  Do your own DD, and I believe, you will come to the same conclusion.

KLDO VIDEO HERE

After listening to this Video and the Interview, there were several things they pointed to, which I’m going to now prove is happening and has happened.  I will give evidence for why the business was delayed until 2013, and I will also explain why I think they are closer now more than ever to breaking their silence. I will now walk you through each major point in the interview, and where KLDO currently stands in regards to each statement.

1. First, Ron Tate explained they were gearing up to springboard into Fitness and Athletic clubs with their Kiosks and PALs system.  He also explains that they have connection with a developing franchise with connections to Golds Gym called Fitness Evolution and they are ready to beta test the kiosks.  So is this true?  Yes, yes it is :) .  Gary Mirsky, head of Sales now for KLDO, a partner, owns Golds Gyms in CA, as well as President of ProClub Management Group in CA, who run SEVERAL GYMS.  In one of Gary’s Gym’s a few people recently checked into Facebook via a KIOSK.  Link Here

As you read on, you will see they are executing even further.

2. Second, Ron stated that in September he was Meeting with billing companies to tie in their billing systems with the Kiosks. Was this true?  Yes, yes it was. In fact, I know they have a partner, and such a good relationship with them, they are attending the IHRSA Trade show, this WEEK.  The world’s leading manufacturers and service providers for the health club industry continually identify the IHRSA Trade Show as the ‘must exhibit’ event of the year.  Please take the quick time to view the below 3 links, which show the connection.  Of Note, I also spoke to Ron, who told me they would have a booth at the show, which led me to the below DD.

NEW PARTNER – PARAMOUNT 

LINK SHOWING PARTNERSHIP      You will also notice Gary Mirsky’s name again at the bottom of the page.

KLDO AND PARAMOUNT AT IHRSA 2013

3. Third, Ron States no current competition in the west.  If you look at IHRSA’s presenters, you will see a true lack of competition.

4. Fourth, Ron stated they planned to be fully functional KIOSK’s in clubs in September of 2012?  That did not happen, but why?  This was the let down that crashed the stock in September of 2012 after it was trading in the $0.004 area.  I called Ron back then, and he stated they ran into a large programming hiccup that kept them from rolling it out, but that in January of 2013, they were back on track.  Below is a job link from KLDO in LATE SEPTEMBER 2012 where they were seeking a programer that could help with the issue.  I again was able to prove he was not lying and that patience would be required.  HERE IS THE JOB LINK

5. Fifth, Ron states they have landed 4 or 5 local schools around Gyms where they will place Water filtration units with 14″ Screens that the PALs system will run on.  They will generate Revenue through the advertisement streams with a 60/40 split.  I’m not sure if this is being executed or not, but will be looking for signs of life over the course of the next few months.

6. Sixth, Ron states that the kiosks have motion activated camera’s that allow people to visually check in via Facebook, Four Square and other social media sites.  As stated previously, I believe Kiosks are already out there using the PALs system.  In one of Gary’s Gym’s a few people recently checked into Four Square/Facebook via a KIOSK.  Link Here .

7. Seventh, Ron mentions that they built a relationship with a time share in Cabo San Lucas that will work as a fulfillment center for the Kiosks as well as give incentives to Gym’s that sign up for certain parts of their PALs system.  Here is the video they developed a while ago:  RESORT VIDEO PARTNER

8. Eighth, Ron mentions that they are having meetings with a MAJOR CASINO to get kiosks placed in them, as well as Hotels, Restaurants, Dental Offices, Doctor Offices, and several others, including Java Juices.  If you notice on the recent check in, it was from a Golds Gym and a Juice bar ;) .  This link here shows they have either gone into Dental/Doctor trade show/conferences, or they are gearing up to go to them: CLICK HERE

9. Ninth, Ron specifically states they will start communicating with investors once they start selling and implementing the business.  WELL FOLKS, we are there.  Now is the time.  As you can tell, Ron and KLDO ARE starting to actively roll out the PALS network and Kiosks all over.  From the Golds Gyms they appear to be in, to the IHRSA convention in Vegas this week, to the conventions they appear to be going to in the Medical and Dental fields.  THE BUSINESS IS HAPPENING.  They fixed their hiccup, but they haven’t lied yet.  They have been working on the BUSINESS, and this company is going to shock investors when they start speaking.  THEY specifically told me that they will speak when Sales start, and that everyone will have a VERY GOOD understanding of whats happening with the business and that they will make SEVERAL ANNOUNCEMENTS as stuff unravels.  The DD/Research here is looking at you in the eye and telling you what most likely lays ahead.  Do you want to wait on them to tell you, or do you want to buy now, and reap the rewards of potential 10,000% gains?  I’ve accumulated shares, and plan to buy more.  I’m not going anywhere on this stock.  I’ve been invested for 7 months now, and salivate when I think about what’s to come.  KIOSKs are the wave of the future, and these guys know what they are doing.  The money is going to start to poor in.  I compare this company to the potential SIRIUS Satellite Radio had when they first started.  A small company with a large idea.  Investors that got in early there, RETIRED.  This is what I focus my time on when I invest in Penny’s.  Not Pump and Dumps.  Company’s that can change investors lives.  AAPT last year had over 10,000% in Gains for anyone that held on the ride up.  I just didn’t have the funds at the time to capitalize on the true potential there.  However, I do now, and I want to make sure everyone else see’s what I see here.

You can also go to the KLDO Ihub board, or the KLDO website to see their brochure for the event. LINK HERE

CHEERS!!!

Continue Reading

Yahoo

Stock Chart

IHUB

Share and Enjoy

  • Facebook
  • Twitter
  • Add to favorites

CYRX – CryoPort Inc.





CryoPort Inc. - CYRX

Date Shares Price
12/28/2012 10,000 $0.300

The most recent addition to my Portfolio is CYRX.  I came across an 8-k for this company when DD’ing it after finding it on a scan.  The 8-k, which they have yet to PR, states the following: “On December 20, 2012, Cryoport, Inc. (“Cryoport”) was engaged by Pfizer, Inc. (“Pfizer”) to manage all domestic and international frozen shipments of their primary animal vaccines. Cryoport will provide on-site logistics personnel and its logistics management platform, the CryoportalTM to manage shipments from Pfizer’s manufacturing site in the United States to its domestic customers as well as to its international distribution centers. As part of its logistics management services, Cryoport will analyze shipping data and processes to streamline logistics, ensuring on-time delivery and the best uses of resources. Initially, Cryoport will manage Pfizer’s total fleet of shippers used for this purpose, including liquid nitrogen shippers and over time will systematically phase-in its patented Cryoport Express® Shippers in conjunction with its on-site logistics team and integrated Cryoportal software.”

This is really big news.  Managing ALL domestic and international frozen shipments for Pfizer’s animal vaccines sounds big enough.  But add in that Pfizer wants Cryoport to provide them with on-site logistics personnel of their own, along with their proprietary logistics software, on an INTERNATIONAL level, it becomes HUGE.  They will then phase in their own shippers.  Essentially, Pfizer just made Cryoport responsible for their entire shipping process in regards to their animal vaccine division, which make no mistake, could grow very easily once shown effective.  As for the revenue potential, I couldn’t begin to project, but I would think millions of dollars on this contract alone.  In addition, it helps them get their foot into the market that they’ve long sought out to control.  I am still researching the relationship they started with Fed-ex back in 2008. It’s also important to note that the officers of this company were Filing form 4′s on December 14th, purchasing hundreds of thousands of shares.

http://www.cryoport.com/

Company Profile

CryoPort, Inc. has developed a game changing solution to the challenge of shipping biological materials, such as vaccines, cell lines, and specimens, under frozen storage conditions. The proprietary CryoPort Express™ solution combines a state-of-the-art web-portal for a time saving / hassle free process with a proprietary dry vapor liquid nitrogen container to make the transport and logistics of sending biological materials easier and more reliable compared to traditional dry ice methods. The turn-key shipping process we have created using new dry vapor container technology maintains -150ºC temperatures for 10+ days and is a ‘green’ game changing alternative to the current hazards and waste created when using dry ice shipping methods.

Now life science companies can outsource the transport logistics to one company that has both the technical understanding for the requirements of frozen transport and the logistical connections to make it happen in a cost effective way. CryoPort has established partnerships with major transportation companies, like FedEx and DHL, allowing us to deliver temperature-sensitive biomaterials in an increasingly complex and time-sensitive global environment.

Cryogenic Technology
CRYOPORT has initiated technological breakthroughs in the field of cryogenic frozen packaging at -150OC, or lower, for the transport of temperature sensitive biological materials with its current reusable shippers now in full production. Three patents for the design of the insulated vacuum vessel have been issued in both domestic and selected overseas countries. In addition, CRYOPORT has completed the development of a unique one-way shipper system, “Cryoport Express”. Cryoport Express has the potential to revolutionize the way the pharmaceutical and biotechnology industries deliver drugs to market and handle specimens in clinical trials, due to its highly efficient design, proprietary technology, ease of use and significant user cost savings. Innovations associated with Cryoport Express will also offer additional intellectual property filings for the Company. No company, other than CRYOPORT, is known to have developed products designed to solve the problems of shipping high value drugs at low temperatures.

MMSTOCKPLAY

Continue Reading

OTC Markets

Share and Enjoy

  • Facebook
  • Twitter
  • Add to favorites

SBFM – Sunshine Biopharma Inc.





Sunshine Biopharma Inc. - SBFM

Date Shares Price
12/12/2012 25,000 $0.25

I found SBFM through some DD I was doing on IHUB.  Earlier this year, CNN.com stated that dying from Cancer 5 years from now, would be as rare as dying from Polio right now.  From that point, I decided that I wanted to find Biotech plays that were looking to find the cure for various forms of Cancer.  Enter Sunshine Biopharma Inc.  Sunshine Biopharma is a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead anti-cancer compound, Adva-27a, just successfully completed their preclinical studies.  Now I won’t begin to tell you that I know everything about this sector, so below is some DD found at this link: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73439197 or you can read below: Sunshine Biopharma, Inc. SBFM

Sunshine Biopharma, Inc. is a Montreal, Canadian based biotech company that is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Aggressive breast cancer has been traced to two key genetic culprits: the HER2 and TOP2 genes. Roche’s Herceptin drug is the standard of care for HER2 positive patients, but there is currently no therapy that targets TOP2.

Enter Sunshine Biopharma

Its flagship compound, Adva-27a, has shown “phenomenal results” in early testing to target and inhibit the Topoisomerase 2 (Top2) enzyme, one of the most important targets for treating aggressive cancer, CFO Camille Sebaaly says in an exclusive interview with BioTuesdays.com.

Proprietary Technology

Many therapeutically important compounds contain diester bonds that link different parts of the molecule together. Diester bonds are naturally unstable often leading to suboptimal performance when the molecule is administered to patients. Diester bonds have specific electrostatic properties and three-dimensional structure that cannot be easily mimicked by other bonds. Chemical structures that do not mimic the diester bond correctly invariably render the compound biologically inactive. In collaboration with Institut National des Sciences Appliquées de Rouen in France (“INSA”), our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere. An isostere is a different chemical structure that mimics the properties of the original. In the body, Carbon-Difluoride compounds are resistant to metabolic degradation but are recognized similarly to the diester containing compounds (see Figure below). This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.

This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. Our in vitro studies have shown that Adva-27a is very effective at killing a variety of cancer types including Multi-Drug Resistant Breast Cancer.

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697.

According to the American Cancer Society:

•Approximately 1.5 million new cases of cancer are diagnosed each year in the U.S.
•Over 11 million Americans are living with cancer.
•Virtually all cancers are either aggressive at the onset or become aggressive over time.
•The overall cost of disease treatment is over $126 billion annually.

Aggressive Cancers

•There are two genes which are associated with aggressive forms of cancer: Her2 and Top2
•Herceptin (R)* is an effective treatment for Her2 positive patients.
•There are currently no effective therapies that target Top 2.
•*Herceptin (R)* sales are $1.8 Billion per year.

The Her2 and Top2 Genes

•Her2 gene encodes Human Epidermal Growth Factor Receptor 2
•Top 2 gene encodes Topoisomerase II, an enzyme that unwinds DNA and is required for cell proliferation.
•Her2 and Top2 are located on Chromosome 17 near the BRCA1 gene at 17q21-q22.
•Top2 is often co-amplified in aggressive cancers.
•As many as 10 copies of the Top2 gene have been found in Multi-Drug Resistant Breast Cancer cells.

Inhibition of the Top2 Enzyme

•Inhibition of Topoisomerase II activity (Top2) is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.

 

SBFM has a current float of under 14,000,000 but has stated that they will need to secure funds to continue to progress with their trials.

MMSTOCKPLAY

Continue Reading

OTC Markets

Stock Chart

IHUB

Share and Enjoy

  • Facebook
  • Twitter
  • Add to favorites

CTIX – Cellceutix Corporation





Cellceutix Corporation – CTIX

Date Shares Price
9/04/2012 15,000 $0.675
Business Description

An early stage developmental biopharmaceutical company…with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.

I can’t even begin to sit here and let you know about everything going on with this company, it would take me weeks.  So below is their current product pipeline, and the links below will help you DD as well.  All I can say is that this has the potential to be the best stock any of you may EVER come accross in your lifetime.  Google CTIX, read below, and you will see why.

We have acquired exclusive rights to several drugs against a number of human diseases. Our current portfolio of product candidates in pre-clinical development include two anti-cancer agents targeting four different tumors (Kevetrin and KM3174); one candidate targeting rheumatoid arthritis (KM277); a small molecule compound with an indication of osteo-arthritis/asthma (KM278); a small molecule compound with an indication of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson’s Disease (KM362) a small molecule compound for the treatment of Psoriasis (Prurisol-KM133) and a small molecule compound for the treatment of autism (KM-391).

Kevetrin Cancer Phase 1
Prurisol Psoriasis Phase 2/3 505(b)(2)
KM 391 Autism Preclinical
KM 227 Arthritis Preclinical
KM 278 Arthritis/Asthma Preclinical
KM 3174 Cancer Early R&D
KM 362 MS/ALS/Park Early R&D
KM 732 Hypertensive emergency Early R&D

See Kevetrin™ – Our lead compound

Prurisol

See KM 133 – Prurisol Compound

KM 391

See KM 391 – Autism Compound

KM 277

In-vivo studies on over 1000 animal subjects have been conducted to check for efficacy of the compound in rheumatoid arthritis. Related in vitro assays including ex-vivo studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the disease

KM 278

This compound showed efficacy in both Osteo-arthritis animal models and Asthma models in animals. We tested the compounds against standard treatment against both asthma and Osteo-arthritis and based on the data. These studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the diseases

KM 362

Demyelination is characteristic in most neurological diseases, where there is no treatment at all, as in case of Lou Gehrig Disease, Parkinson’s Disease and Multiple Sclerosis, etc. Initial study results are conclusive of the compounds ability to target all of these neurological diseases. These early studies indicate this compound aids in myelination along with strengthening the functions of the nerves, spinal cord and the brain tissue.

KM 3174

This is a very early stage developmental compound in the treatment of cancer. After additional in vitro and in vivo studies the Company will determine whether to advance this compound for further development.

KM 732

A small molecule which shows properties in the reduction of high blood pressure.

Preliminary testing in rats revealed that test animals showed a significant decrease in both systolic and diastolic blood pressure compared to controls, with no apparent toxicity. Clinical observation of the animals indicated that blood pressure was reduced within a few minutes of the administration of the compound. The Company plans to conduct proof of concept studies in large animals to evaluate the compound’s potential for development to treat hypertensive emergency. Hypertensive emergency is a potentially life-threatening condition characterized by uncontrolled blood pressure leading to damage to other organs.

Hypertensive emergency is a serious condition affecting over 500,000 Americans per year, thus warranting our early investigational efforts into KM732.

MMSTOCKPLAY

Continue Reading

OTC Markets

Stock Chart

IHUB

Share and Enjoy

  • Facebook
  • Twitter
  • Add to favorites